The frequent recurrence of focal segmental glomerulosclerosis (FSGS) in renal allografts (1) has led to renewed interest in the various plasma factors found to increase glomerular permeability to proteins (2, 3). Several methods of isolating these factors have been described (2), but their chemical structure and precise role in causing nephrotic proteinuria remain unclear. Yet their recognition has led to attempts to remove them from the plasma in an effort to control the disease. The most obvious strategy was immunosuppression, in the hope that this would lower the production of these circulating factors (4). The next logical step was to try to remove these factors by plasma exchange.
In this editorial we analyze the efficacy of plasmapheresis in the treatment of idiopathic FSGS occurring in the native kidney or recurring in the renal transplant. The difficulty of this endeavor lies in the fact that the various studies of this subject have only had few patients, have not been controlled for variables such as volume or number of plasma exchanges or concomitant immunosuppression, have not used comparable definitions of remission of the nephrotic syndrome or improvement of renal function, and have had relatively short follow up. None of them have been randomized or controlled.
We have, therefore, used reasonable criteria by which to evaluate these studies. We defined complete remission of proteinuria as <300 mg/day, partial remission as <2 g, and relative remission as a decrease of protein excretion by ≥ 50%. We defined renal function as improved if serum creatinine declined by ≥1 mg/dl, stable if it did not rise, worse if it increased by ≥ 50%, and end-stage if the patient needed dialysis. The results of the studies in native and transplanted kidneys are shown in Tables I and II. Plasmapheresis in native kidneys (Tab. I) Studies of plasmapheresis in steroid resistant FSGS are uncontrolled and include only few patients. Feld and her colleagues treated eight patients for a total of six exchanges over a two-week period (5): one had a partial remission, but seven had no response. Renal function remained stable in only three patients, but worsened in another three, and two developed end-stage renal failure. The authors speculated that treatment was started too late in the disease, when irreversible structural changes would have nullified any benefit obtainable from removing the factor. These patients had been nephrotic for about one year before undergoing plasmapheresis.
Ginsburg and Dau described a patient started on plasma exchange 18 months after the onset of steroid resistant FSGS. Proteinuria decreased from 8.8 to 2.0 gms after one month of weekly plasma exchanges, serum creatinine declining from 2.9 to 1.0 mg/dl. There was a prompt worsening of proteinuria and renal function on stopping treatment, but there was further response when plasma exchanges were resumed (6).
A larger number of patients was reported by Mitwali, eleven nephrotic patients who had failed steroids and cyclophosphamide (7). Using plasmapheresis for 17 sessions over a period of six months, these authors found that proteinuria decreased from 5.3 to 1.4 gms and serum creatinine from 2.6 to 2.2 mg/dl. After a follow up period of some two years, six patients were in sustained partial remission, three patients had no response, and two patients had a relative remission. Renal function was stable in six, but worsened in three, and two developed end-stage renal disease.
Viewed in total these results are not impressive, suggesting that plasmapheresis is not an attractive option for the treatment of FSGS in the native kidney.
Plasmapheresis in recurrent FSGS in the transplanted kidney (Tab. II)
For recurrent FSGS in the transplanted kidney plasmapheresis has been tried more often. Earlier reports had few patients and showed poor response. Thus Dantal et al described nine patients collected over 12 years and treated by plasma exchange six to ten times over 8 to 20
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The role of plasmapheresis in the treatment of focal segmental glomerulosclerosis (FSGS) days (8). The outcome was variable, four patients demonstrating partial or relative remissions, while five others showing no response. Renal function remained stable in four patients, worsened in two, and three patients went on dialysis.
A few years later Li and his colleagues reviewed the literature and identified 20 patients from five studies (including the Dantal study and their own case report) (9). They divided the patients into three groups. Group A (n=7, mean pretreatment proteinuria 8.8 g) showed a "good response" to plasma exchange, marked by proteinuria declining to less than 1 g. Group B (n=6, mean pretreatment proteinuria 4.8 g) had a partial response to plasma exchange, proteinuria dropping to less than 50% of pretreatment values (included in this group were patients who relapsed after stopping the plasma exchange). Group C patients (n=7) did poorly, having no remission of proteinuria (pretreatment vs post treatment proteinuria 15.3 g vs 17.3 g) and progressing to renal failure. The average number of plasma exchange treatments was similar among the three groups (8.8 vs 6.2 vs 7.6), and the follow up period ranged from 11 to 21 months.
In the following year Artero and her colleagues reported on plasmapheresis in nine patients, all of whom had varying degrees of remission after a total of nine sessions each (10) . Renal function improved in two, remained stable in four, but worsened in three, two of whom needed dialysis. The authors attributed success to starting plasmapheresis immediately upon diagnosing FSGS, and regarded the lack of significant hyalinosis on kidney biopsy n = number of patients; F/U = follow up; L = liter; pv = plasma volume; n/a = data non available; * = median/range; ** = see text for definition; † = end-stage renal disease as a good prognostic feature. By applying a novel in vitro testing method these investigators also demonstrated the ability of the pretreatment plasma to injure the glomerular basement membrane. Plasmapheresis removed the factor that injured the glomerular permeability barrier.
More recently Andresdottir and colleagues reported seven patients with recurrent FSGS (pretreatment proteinuria 5.8±4.8 grams) treated with ten treatment sessions of plasma exchange, comparing them with ten historical controls (proteinuria 5.5±3.4 grams) (11) . Two of the seven treated patients lost their graft from rejection; in the remaining five proteinuria disappeared abruptly after plasma exchange, but reappeared promptly in two upon stopping the treatment. The relapsers responded to further plasma exchange (mean follow up period 1.7 years). Of the seven historical controls, five lost their graft due to recurrence of FSGS over a mean follow up period of 3.6 years.
Several authors have combined plasmapheresis with immunosuppression in an attempt to suppress the production of the putative permeability factor as well as removing it. Mowry et al combined high doses of cyclosporine (mean dose 22.8 ± 8.7 mg/kg/day) with plasmapheresis (4). Of eight patients (including three who received plasma exchange alone) two lost their graft, and six had a relative remission of proteinuria. The precise duration of follow up was not given. There are two other single case reports of high doses of cyclosporine or cyclophosphamide combined with plasmapheresis causing remission of nephrotic syndrome (12, 13) .
Prophylactic plasmapheresis
In view of the high rates of recurrence of FSGS some centers have tried prophylactic plasmapheresis before transplantation. Kawaguchi et al (14) reported on fourteen children: seven received two to three plasmaphereses (at -5, -3, and -1 day) before transplantation: 67% of untreated children had recurrent FSGS compared to only 37% who had plasmapheresis.
Iguchi et al also tried prophylactic plasmapheresis (3 sessions) before transplantation in three patients, only one of whom had recurrence of proteinuria compared to four out of eight not receiving plasmapheresis (15) . Two of the patients who had recurrence of FSGS had further plasmapheresis with one showing relative remission and stable renal function, while the other developing graft failure.
CONCLUSIONS
Although the identification of permeability factors in the plasma of patients with recurrent FSGS would provide the underpinning of a scientific basis for performing plasmapheresis, the use of this procedure in patients with native kidneys has not been successful. Plasmapheresis may be useful in managing post transplant recurrent FSGS and may have a preemptive role in patients at high risk of developing recurrent disease; but firm conclusions cannot be made about its efficacy in those circumstances either, because of the small number of patients, the short follow up, and the lack of standardized definitions of good response. Many more patients will have to be treated with a standard plasmapheresis protocol in a controlled prospective fashion before a final judgment can be made about the merit of plasmapheresis in focal segmental glomerulosclerosis.
